中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.024 seconds)

    3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS
    6.
    发明申请
    3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS 审中-公开

    公开(公告)号：US20180170921A1

    公开(公告)日：2018-06-21

    申请号：US15900043

    申请日：2018-02-20

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne BOUILLOT ,  Alexis Denis ,  John Liddle ,  Ann Louise Walker

    IPC: C07D413/12

    CPC classification number: C07D413/12

    Abstract: The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

    3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
    7.
    发明授权
    3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors 有权

    公开(公告)号：US09932328B2

    公开(公告)日：2018-04-03

    申请号：US15537805

    申请日：2015-12-17

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne Bouillot ,  Alexis Denis ,  Ann Louise Walker ,  John Liddle

    IPC: A61K31/416 ,  C07D413/12

    CPC classification number: C07D413/12

    Abstract: Compound of formula (I) wherein: R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ═O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

    3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors
    9.
    发明授权
    3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors 有权

    公开(公告)号：US10273232B2

    公开(公告)日：2019-04-30

    申请号：US15900043

    申请日：2018-02-20

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne Bouillot ,  Alexis Denis ,  John Liddle ,  Ann Louise Walker

    IPC: C07D413/12

    Abstract: The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

    COMPOUNDS
    10.
    发明申请
    COMPOUNDS 审中-公开

    公开(公告)号：US20190100517A1

    公开(公告)日：2019-04-04

    申请号：US16207745

    申请日：2018-12-03

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne Bouillot ,  Alexis Denis ,  John Liddle ,  Ann Louise Walker

    IPC: C07D417/12

    Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ═O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Patent Agency Ranking